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BACKGROUND: Consumers may seek health advice
from health food store employees (HFSEs) and pharma-
cists. Delays in the diagnosis of time-critical illnesses
may increase the likelihood of morbidity, mortality and
healthcare expenditures.
OBJECTIVE: To describe the information provided by
HFSEs and pharmacists for symptoms of undiagnosed
Type 1 diabetes.
DESIGN: A standardized actor portrayed a consumerwith
symptoms of Type 1 diabetes at eight community phar-
macies and 12 health food stores (HFSs) in Pittsburgh,
Pennsylvania, and Chapel Hill and Durham, North
Carolina. He inquired about potential diagnoses, the
need to see a physician, and product recommendations.
SUBJECTS: The subjects included twelve HFSEs and
eight licensed pharmacists.
RESULTS: Four of eight (50%) pharmacists and two of 12
(17%) HFSEsmentioned diabetes as a potential diagnosis.
Although six pharmacists recommendedurgent physician
follow-up, only two HFSEs did so; two HFSEs explicitly
advised against a physician visit. One pharmacist recom-
mended a product. NineHFSEs recommended at least one
product (monthly costs, range: $24.70–$209.96).
CONCLUSIONS:Even when presented with classic symp-
toms of Type 1 diabetes, under-recognition of diabetes
was common among HFSEs and community pharma-
cists. Delays in treatment present a health risk to
consumers. Further research could confirm these results
and inform educational interventions to improve diabetes
recognition by both groups.
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INTRODUCTION
In 2007, approximately 38% of American adults reported using
complementary and alternative medicine (CAM) during the
previous year.1 Common reasons for CAM use include disease
prevention,1–3 chronic disease therapy (e.g., arthritis, cancer,
depression),1–5 and treatment of symptoms,1–3 including those of
diabetesmellitus.6,7 Among CAMmodalities, dietary supplement
use is most common, with 17.7% of American adults reporting
using these products.1 Sales of dietary supplements in the U.S.
have grown from $8.8 billion in 19943 to $14.8 billion in 2007.8
Consumers may seek information about CAM from various
sources, including health food store employees (HFSEs).9–11
Given that HFSEs are not required to have formal training or
be licensed9,11 their advice may be incomplete or inappropri-
ate.9,10 Previous studies examining the advice provided by
HFSEs to simulated shoppers with a “documented diagnosis”
(e.g., breast cancer, HIV infection) found that their recom-
mendations vastly diverged from standards of care. Their
advice ranged from expensive and potentially contraindicated
products10–12 to one HFSE who advocated discontinuing
tamoxifen for breast cancer.10
Although prior studies examined the advice provided by
HFSEs for specific diagnoses, people often use CAM to treat
their symptoms.1,2,13 Thus, it is important to examine the
advice provided to consumers who present to HFSEs with
symptoms, particularly those associated with a serious illness.
We conducted a pilot study to examine advice provided by
HFSEs and community pharmacists to someone with symp-
toms of Type 1 diabetes. Diabetes is a prevalent condition with
distinctive symptoms14 and can pose significant health risks if
untreated, especially for Type 1 diabetes.15,16 We included
community pharmacists because they often provide health
advice to consumers,17,18 including CAM-related informa-
tion.17,19 To our knowledge, no study examined pharmacists’
advice regarding undiagnosed Type 1 diabetes. We examined
whether HFSEs and pharmacists: (1) recognized the symptoms
of diabetes; and (2) recommended physician follow-up for these
symptoms. In addition, we examined the monthly costs of
recommended products.
METHODS
The study protocol was approved by the University of North
Carolina Institutional Review Board. Because informing sub-
jects about the study would likely influence their behaviors
and bias our results, we were permitted a waiver of informed
consent. For this reason, we could not collect data on the
subjects’ demographic characteristics, except for gender. Data
were collected between December 2008 and March 2009.
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Study Sample
We used Internet phonebooks to identify HFSs and chain
pharmacies in Chapel Hill and Durham, NC, and Pittsburgh,
PA. We targeted chain pharmacies because, compared to
independent pharmacies, they account for far greater retail
sales and aremore likely to have standard training protocols.We
excluded HFSs that were ethnically-focused (e.g., Latino tien-
das, Ayurveda) or affiliated with practitioners (e.g., acupunctur-
ists, chiropractors). From this list, we selected a convenience
sample of 12 HFSs (six affiliated with national chains, and six
independent) and eight pharmacies from three national chains.
One subject (HFSE or licensed pharmacist) was selected at each
site. If two HFSEs/pharmacists were present, the actor inter-
acted with the first individual who approached him. Student
pharmacists and pharmacy technicians were excluded.
Procedures
To assess the subjects’ actual behaviors, we used a standardized
actor posing as a customer, a strategy that has been used
successfully in previous studies of HFSs 10,12 The actor was a
22-year-old, thin, Caucasian male who described an indolent
onset of diabetes symptoms (malaise, fatigue, poor concentra-
tion, polyphagia, weight loss, polydipsia, and polyuria); the
literature indicates that some adults who develop Type 1 diabetes
have a prolonged onset of symptoms.20 According to the script
(Fig. 1), he recently moved to the area for graduate school and
lacked a primary care physician. For credibility, his symptoms
were framed in terms of poor academic and social performance.
He wore form-fitting clothing and carried a nearly-empty water
bottle to each visit. He inquired about potential diagnoses for his
condition, and asked for recommendations to alleviate his
symptoms. If by the end of the interview, the subject had not
voluntarily recommended a physician visit, the actor asked (i.e.,
“prompted”) whether he should do so and over what time frame.
The actor completed a data collection form immediately after the
visit. Each visit lasted approximately 10–15 minutes.
We approached quality control in two ways. First, two
academic internists reviewed our script for clinical plausibility.
Second, issues that arose during data collection, coding, and
analysis were discussed and resolved at weekly meetings.
Measures
We had three primary outcomes: (1) Recognition of diabetes as
a potential diagnosis (mentioned explicitly or as part of the
differential diagnosis); (2) Recommendation for physician follow-
up; and, (3) Recommended products and their monthly costs. All
three authors independently coded the outcomes using the
actor’s field notes. Recommendations for physician follow-up
were coded as three dichotomous variables: whether a recom-
mendation wasmade; whether it was unprompted; and, urgency
of follow-up (i.e., within 1 week). Recommended products were
classified according to their primary ingredients. On rare occa-
• “I just moved here for grad school at UNC.”  
• “I haven’t found a doctor yet here - I’ve just been too busy.” 
 “I’ve done the herbal thing in the past, so I figured I’d give it another go.” 
• “I’m usually pretty healthy, I’d say. I watch what I eat, and exercise a few times a 
week, depending on how busy I am.”
Introduction 
• “So, I haven’t really been feeling like myself for the past few weeks.”  
• “I’ve been more tired than usual lately. I’ve noticed that I’ve been dozing 
off in class, even though I’ve been getting plenty of sleep.”  
• “I keep drinking Diet Mountain Dew, and it’s not like the caffeine is 
working. All I’m doing is just going to the bathroom constantly!” 
• “I’ve been eating a lot, too, but it’s not like I’ve gained any weight. 
Actually, I’m pretty sure I’ve lost some weight!” 
Diabetes 
disclosure 
•  If in pharmacy: “Is there anything I can take without a prescription?” OR if in health food store: “Is there anything 
you recommend I take?” 
• “I’m pretty sure that I can get my mom to pay for these [supplements]. I need to run them by her first, so do you 
mind if I write them down?”  
• “How long do I need to take this for? I’m just trying to figure out how much this will put her back.”  
• “Since she can be pretty cheap sometimes, is there one [product] that you think I have to buy?”  
• “What’s this [product] supposed to take care of?” 
• “How long is it going to take to work? I’m getting more and more tired every day.” 
• “Are there any side effects I should watch out for?” (If interviewee doesn’t voluntarily disclose) 
• Do you think I should see a doctor about this?” (If interviewee doesn’t voluntarily recommend) 
o  “How soon do I need to see a doctor?” 
Product probes 
Physician need & 
urgency
For realism, the flow of conversation was allowed to vary naturally between individual visits, as appropriate; however, all seven symptoms of 
Type 1 diabetes were disclosed at every visit.
 probes 
Figure 1. Type 1 diabetes mellitus script used by our standardized actor during site visits.
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sions when there were disagreements, we resolved differences
through discussion during weekly meetings. We also calculated
the monthly product costs based on the minimum amount of




Four of the eight (50%) pharmacists mentioned diabetes as a
potential diagnosis (Table 1); pharmacist stated that diabetes
was not a possible diagnosis. Other diagnoses mentioned by
pharmacists included infectious mononucleosis and a malab-
sorptive disorder. In contrast, two of 12 (17%) HFSEs men-
tioned diabetes as a potential diagnosis. The remaining ten
offered various diagnoses (e.g., “adrenal exhaustion,” anorexia,
“mold infestation”).
Physician Follow-Up
All eight pharmacists recommended a physician visit, seven
(88%) of whom did so without prompting. Six pharmacists
recommended an urgent (i.e., < 1 week) visit. Of 12 HFSEs,
three (25%) made an unprompted recommendation for a
physician visit, and three recommended a visit only after being
prompted. Of the 6 HFSEs recommending a physician visit,
two (33%) recommended an urgent visit. Interestingly, two
HFSEs stated that a physician visit was unnecessary, and two
others (both independent stores) explicitly advised against a
physician visit. Their rationale was that the physician would
likely overlook the underlying illness (“mold infestation” and
“adrenal exhaustion”). One subject further cautioned that a
physician would “just give [the actor] Ritalin” to curb fatigue.
Recommended Products
Only one pharmacist recommended a product—a multivitamin
with a monthly cost of $13.99. Conversely, all six independent
and three of the six (50%) chain HFSEs recommended at least
one product. Independent HFSEs often recommended herbal
products, whereas chain-affiliated HFSEs frequently offered
proprietary multivitamins. The most common ingredients
(across all products) included Rhodiola rosea, Ashwagandha,
Ginseng, and Guarana. Independent HFSEs recommended
more products than those in chain HFSEs (mean: two versus
one, respectively, data not shown). The total monthly costs for
Table 1. Results of Interactions with Pharmacists and Health Food Store Employees (HFSEs) by a Standardized Actor Describing Undiagnosed
Type 1 Diabetes Symptoms
Pharmacists (n=8) HFSEs (n=12)
Site characteristics
Chain-affiliated store 8 6





Did not mention diabetes 3 10
Mean number of diagnoses offered 1 1.25
Alternate diagnoses offered (n) Malabsorptive disorder (1) Adrenal fatigue (3)









Suggested visit-unprompted 7 (6 urgent) 3 (2 urgent)
Suggested visit-prompted 1 3
Considered visit unnecessary 0 4
Missingb - 2
Product recommendations
Recommended at least 1 product 1 9
Mean recommendations (range) 0 (0-1) 1.3 (0–3)
Total monthly cost of products, rangec 13.99 24.70–209.96





aThis variable was classified as “potential” if the diabetes was mentioned explicitly as a potential diagnosis or as part of the differential diagnosis. If the
subject explicitly stated that diabetes was not a potential diagnosis, then this variable was classified as “eliminated”
bTwo interviews were terminated before the actor was able to inquire about physician recommendations
cMonthly cost of all products recommended at each site. Prices do not reflect discounts and do not include sales tax
dProduct classifications generally follow the conventions described by the United States Pharmacopeia and the Dietary Supplement and Health Education
Act of 1994
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all products recommended by HFSEs ranged from $24.70 to
$209.96, with recommendations from chain HFSEs being
costlier than independent HFSEs (range: $49.99–$209.96
and $24.70–$73.44, respectively).
DISCUSSION
This pilot study is the first to report advice provided by HFSEs
and community pharmacists to a standardized actor who
portrayed undiagnosed Type 1 diabetes symptoms. We wish
to highlight three findings. First, under-recognition of diabetes
was common in both groups, even though a young, thin
person described classic symptoms of Type 1 diabetes.
Although pharmacists were more likely to consider diabetes
as a potential diagnosis than HFSEs (50% vs. 17%), we were
surprised that half of the pharmacists did not recognize this
diagnosis in someone describing hallmark symptoms. Second,
six of eight (75%) pharmacists and 2 of 12 (17%) HFSEs
recommended that the actor see a physician within a week.
Notably, 4 HFSEs told the actor that a physician visit was
unnecessary; in two of these instances, the actor was explicitly
discouraged from seeing a physician. Lastly, nine HFSEs
recommended products that were often expensive. Failing to
see a physician and using CAM could delay the diagnosis and
appropriate management of Type 1 diabetes and lead to
serious consequences.15,20
Although our findings are novel, this study has several
limitations. First, we used a single actor. Although he used a
script to standardize the interactions, it is possible that
pharmacists and HFSEs were influenced by characteristics of
our actor. Second, we could neither audiotape discussions nor
collect individual data on subjects without informed consent.
This limited our ability to conduct additional analyses. Third,
our study was small and limited in geographic scope, and
independent pharmacies were excluded, which may limit the
generalizability of our findings. Lastly, potential heterogeneity
in advice received from different pharmacists and HFSEs is
limited, as we interviewed only one subject per site.
CONCLUSIONS
We provide preliminary empirical evidence that advice provided
by HFSEs and community pharmacists may be both inappro-
priate, and potentially harmful, to persons with potentially
time-critical illnesses (e.g., Type 1 diabetes). Clinicians should
be aware of the potential misinformation regarding symptom
management being provided elsewhere. Future research
should be performed to confirm our findings in a larger sample
and determine whether the results generalize to other condi-
tions. Such data could be used to develop strategies that help
HFSEs and pharmacists recognize when a referral to a
physician may be necessary.
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